Lavipharm S.A.

LAVI

GRS246003008

Pharmaceuticals

Market Closed - Athens S.E. Other stock markets 10:11:39 2024-07-16 am EDT			5-day change	1st Jan Change
0.923 ^EUR	+0.33%		+5.73%	+15.95%

Feb. 28	Lavipharm S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Lavipharm S.A. entered into a new asset purchase agreement to acquire Flagyl product line for Greek market from Sanofi.	CI

Lavipharm S A : Announcement 4879/2024

June 17, 2024 at 09:43 am EDT

This Announcement is available only in Greek.

Attachments

Original Link
Permalink

Disclaimer

Lavipharm SA published this content on 17 June 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 17 June 2024 13:42:06 UTC.

Latest news about Lavipharm S.A.

Lavipharm S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
Lavipharm S.A. entered into a new asset purchase agreement to acquire Flagyl product line for Greek market from Sanofi.	Dec. 10	CI
Lavipharm S.A. signing of an asset purchase agreement to acquire Lonarid N and Lonalgal from Boehringer Ingelheim International GmbH.	Nov. 30	CI
Lavipharm S.A. Reports Earnings Results for the Nine Months Ended September 30, 2023	Nov. 08	CI
Lavipharm S.A. Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-21	CI
Lavipharm S.A.(ATSE:LAVI) added to ATHEX Composite Index	23-06-21	CI
Lavipharm S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-04	CI
Lavipharm S.A. Reports Earnings Results for the Half Year Ended June 30, 2022	22-09-15	CI
Lavipharm S.A. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-21	CI
Lavipharm S.A. Auditor Raises 'Going Concern' Doubt	22-03-20	CI
Lavipharm S.A. Reports Earnings Results for the Half Year Ended June 30, 2021	21-09-29	CI
Lavipharm S.A. Reports Earnings Results for the Full Year Ended December 31, 2020	21-04-26	CI
Lavipharm S.A. Auditor Raises 'Going Concern' Doubt	21-04-25	CI
Zentiva Reinforces Its Presence in Greece by Signing A Partnership with the Company Lavipharm S.A	20-10-19	CI
Lavipharm S.A. Auditor Raises 'Going Concern' Doubt	20-05-07	CI
Lavipharm S.A. Auditor Raises 'Going Concern' Doubt	19-04-24	CI
Lavipharm S.A. Auditor Raises 'Going Concern' Doubt	18-04-26	CI
Lavipharm Announces Consolidated Earnings Results for the First Half of 2015	15-09-21	CI
Robertet SA and Codif Recherche & Nature acquired Hitex S.A. from Lavipharm S.A. for €3.1 million.	13-12-31	CI
Lavipharm S.A. Announces Earnings Results for the Year Ended December 31, 2011	12-09-25	CI
Lavipharm S.A. Reports Consolidated and Parent Earnings Results for the Second Quarter and Six Months Ended June 30, 2012	12-08-29	CI
Lavipharm SA Reports Consolidated and Company Earnings Results for the First Quarter Ended March 31, 2012	12-05-29	CI

Chart Lavipharm S.A.

Duration

Period

More charts

Company Profile

Lavipharm SA is a Greek commercial and industrial enterprise engaged in the development, manufacture, marketing and distribution of pharmaceutical, cosmetic and over-the-counter (OTC) products. Its main pharmaceutical products cover such categories as anti-inflammatory, asthma controlling, neurological, antiseptic, analgesic, dermatological and gastrointestinal therapies. Its cosmetic products are offered under the brand names of Castalia Soins Dermocosmetiques and Laviderm Active Technology and are used for skin, face and body care, as well as for scalp and hair problems. Its OTC products include cold and flu remedies, oral care, dermatological products, condoms, antiseptics, analgesics, laxatives and gynecology products. It is the parent company of Lavipharm Group of Companies. In January 2014, Robertet SA acquired together with CODIF the HITEX company, specialized in subcontracting of carbon dioxide extraction, from Lavipharm SA.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
LAVIPHARM S.A.	+15.95%	169M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+25.40%	45.54B
OTSUKA HOLDINGS CO., LTD.	+34.52%	24.51B
SANDOZ GROUP AG	+27.12%	16.48B
CIPLA LIMITED	+21.19%	14.66B
ZYDUS LIFESCIENCES LIMITED	+71.91%	14.3B
THE MEDICINES COMPANY	-0.05%	6.79B
ONO PHARMACEUTICAL CO., LTD.	-11.84%	6.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+18.15%	5.87B
STADA ARZNEIMITTEL	-8.87%	5.73B